US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
4 deals · US$431mdisclosed · Life Sciences · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Dec 2025 | Freenome | – | – | Placement | Completed | 240.0 | Diagnostics+2 | Goodwin (issuer)Jefferies (lead manager)Leerink Partners (lead manager)White & Case (lead manager) |
| Apr 2026 | Alamar Biosciences | – | – | IPO | Listed | 191.3 | Life Sciences+1 | Cooley (issuer)J.P. Morgan (lead manager)BofA Securities (lead manager)TD Securities (lead manager)Leerink Partners (lead manager)Stifel (lead manager)Latham & Watkins (lead manager) |
| May 2026 | Conexeu Sciences | – | – | Direct listing | Announced | – | Life Sciences | H.C. Wainwright & Co. (issuer) |
| Jul 2026 | Codexis | – | – | Follow-on offering | Completed | – | Biotech+1 | Piper Sandler (lead manager) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built